Beverly Hills Private Wealth LLC Invests $213,000 in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Beverly Hills Private Wealth LLC purchased a new stake in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 9,657 shares of the company’s stock, valued at approximately $213,000.

Several other institutional investors and hedge funds have also bought and sold shares of TEVA. Oarsman Capital Inc. purchased a new stake in Teva Pharmaceutical Industries in the fourth quarter worth $29,000. Marshall & Sterling Wealth Advisors Inc. purchased a new stake in shares of Teva Pharmaceutical Industries in the 4th quarter worth about $44,000. Wilmington Savings Fund Society FSB purchased a new position in Teva Pharmaceutical Industries during the 3rd quarter valued at about $50,000. Ameliora Wealth Management Ltd. bought a new stake in Teva Pharmaceutical Industries during the fourth quarter worth about $66,000. Finally, IFP Advisors Inc grew its holdings in Teva Pharmaceutical Industries by 96.1% in the fourth quarter. IFP Advisors Inc now owns 3,999 shares of the company’s stock worth $88,000 after purchasing an additional 1,960 shares during the period. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently commented on TEVA. Bank of America dropped their price target on Teva Pharmaceutical Industries from $23.00 to $20.00 and set a “buy” rating on the stock in a research report on Thursday, March 6th. Piper Sandler raised their price target on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an “overweight” rating in a report on Friday, January 17th. Barclays dropped their price target on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating on the stock in a research note on Thursday, January 30th. StockNews.com raised shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a report on Wednesday, April 23rd. Finally, Hsbc Global Res raised shares of Teva Pharmaceutical Industries to a “strong-buy” rating in a research report on Monday, April 28th. One investment analyst has rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $23.43.

Teva Pharmaceutical Industries Stock Performance

Shares of NYSE TEVA opened at $16.40 on Tuesday. The company has a current ratio of 0.98, a quick ratio of 0.75 and a debt-to-equity ratio of 2.97. Teva Pharmaceutical Industries Limited has a 12-month low of $12.47 and a 12-month high of $22.80. The firm has a market capitalization of $18.59 billion, a price-to-earnings ratio of -11.31, a price-to-earnings-growth ratio of 1.44 and a beta of 0.62. The firm has a 50 day moving average of $15.10 and a 200 day moving average of $17.48.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.